India  

Phase 1 trial results show Covaxin has tolerable safety, enhanced immunity: Lancet study

IndiaTimes Friday, 22 January 2021
India's first indigenous vaccine against COVID-19, Covaxin, showed enhanced immune response without any serious side effects in the participants enrolled for the phase 1 trials, according to the results published in The Lancet Infectious Disease journal. Developed by Bharat Biotech in collaboration with the ICMR and the National Institute of Virology (NIV), Pune, the vaccine has been granted emergency use authorisation in clinical trial mode' by the Indian government.
0
shares
ShareTweetSavePostSend
 

You Might Like


💡 newsR Knowledge: Other News Mentions

BBV152 BBV152 Vaccine against COVID-19

They thought they got the Covid-19 vaccine. They were part of a trial instead [Video]

They thought they got the Covid-19 vaccine. They were part of a trial instead

More than a dozen slum residents in Bhopal, India, say they thought they were being vaccinated for Covid-19. They say they later discovered from local activists that some of them hadn’t been given an approved vaccine and had unwittingly taken part in a Phase 3 clinical trial for India’s homegrown vaccine, Covaxin. CNN’s Vedika Sud reports.

Credit: Bleacher Report AOL    Duration: 03:42Published

Brazil to buy 20 million Covid-19 vaccines from India's Bharat Biotech

Brazil's health ministry on Thursday signed a contract to purchase 20 million doses of Covaxin, the Covid-19 vaccine made by India's Bharat Biotech, for delivery..
IndiaTimes
"Covaxin is successful in tackling UK strain," informs ICMR [Video]

"Covaxin is successful in tackling UK strain," informs ICMR

Indian Council of Medical Research DG, Balram Bhargava announced that the Covaxin is successful in tackling UK strain. He further informed that UK variant strain is now present in 70 countries and 164 cases have been identified in India. "UK variant strain is now present in 70 countries and we've identified 164 cases of it in India. We were able to find the first case of the UK variant on 22nd-23rd December. In a week's time, we were able to collect blood from these patients and culture the strain. We found that the neutralisation of UK strain was equivalent to Indian strains circulating in India. It's a very reassuring news that UK variant can be tackled by this vaccine," informed ICMR DG during a press briefing on January 28.

Credit: ANI    Duration: 01:55Published

Coronavirus disease 2019 Coronavirus disease 2019 Disease caused by severe acute respiratory syndrome coronavirus 2

India reports 16,488 new COVID cases [Video]

India reports 16,488 new COVID cases

On February 27, total COVID-19 tally of India reached to 1,10,79,979. The country reported 16,488 new COVID-19 cases in last 24 hours and active cases stand at 1,59,590. With new 12,771 discharges, total number is at 1,07,63,451. 113 deaths were reported in last 24 hours, taking cumulative toll to 1,56,938. 1,42,42,547 beneficiaries have been vaccinated for COVID-19 across India.

Credit: ANI    Duration: 01:04Published
Poles go underground for COVID treatment [Video]

Poles go underground for COVID treatment

A UNESCO World Heritage site in Poland is being used to help people recover from COVID-19, with patients going deep underground in the Wieliczka salt mine to a therapeutic centre dealing with respiratory illness. Libby Hogan reports.

Credit: Reuters Studio    Duration: 01:33Published

COVID-19: DGCA extends suspension of commercial international flights till THIS date, check details here

Even though international commercial flights will stay suspended, certain international scheduled flights will be allowed to operate on select routes.
DNA

MHA extends guidelines on Covid-19 till March-end

The home ministry on Friday extended the validity of existing guidelines for surveillance, containment and caution against Covid-19 to March 31. In a statement,..
IndiaTimes

National Institute of Virology Indian virology research institute

Bharat Biotech vaccine could've advantage over others on new strain, hopes ICMR DG [Video]

Bharat Biotech vaccine could've advantage over others on new strain, hopes ICMR DG

Director General of ICMR, Dr. Balram Bhargava, said that indigenously developed Bharat Biotech vaccine might have some advantages over other vaccines on the new strain of COVID that was found in UK. He said, "NIV scientists have successfully isolated the new virus strain and this will be tested against different vaccines. We hope potentially Bharat Biotech vaccine will have some advantages over other vaccines on this new strain because it is a whole virus." "New virus variant which is now more than 60% infective and creating havoc in the UK is worrisome. There are 29 patients in India with the same variant for which we should be cautious. We have been able to isolate the new virus very soon," added Dr. Balram Bhargava.

Credit: ANI    Duration: 01:49Published

Indian Council of Medical Research Indian Council of Medical Research

COVID: India reports 16,577 new cases [Video]

COVID: India reports 16,577 new cases

On February 26, total COVID-19 tally of India reached to 1,10,63,491. The country reported 16,577 new COVID-19 cases in last 24 hours and active cases stand at 1,55,986 . With new 12,179 discharges, total number reached to 1,07,50,680. 120 deaths were reported in last 24 hours, taking cumulative toll to 1,56,825. 1,34,72,643 beneficiaries have been vaccinated for COVID-19 across India. According to ICMR, total number of samples tested up to Feb 25 is 21,46,61,465 including 8,31,807 samples tested yesterday.

Credit: ANI    Duration: 01:19Published
COVID: Spike of 16,000 cases in India [Video]

COVID: Spike of 16,000 cases in India

On February 25, the total COVID-19 tally of India reached to 1,10,46,914. The country reported 16,738 new COVID-19 cases in last 24 hours and active cases stands at 1,51,708. With new 11,799 discharges, total number reached to 1,07,38,501. 138 deaths were reported in last 24 hours, taking cumulative toll to 1,56,705. 1,26,71,163 beneficiaries have been vaccinated for COVID-19 across India. According to Indian Council of Medical Research (ICMR), 21,38,29,658 samples tested up to 24th February.

Credit: ANI    Duration: 01:53Published

No evidence so far to link surge in Covid cases to new variants: ICMR

Even as some states witness a sudden spike in Covid cases, the scientific evidence so far does not suggest any link between new variants of coronavirus detected..
IndiaTimes

India's COVID-19 vaccines will be effective against new variants: ICMR

Stressing on the efficacy of indigenous COVID-19 vaccines, the Indian Council of Medical Research (ICMR) on Thursday said interim results of the ongoing clinical..
DNA

Bharat Biotech Bharat Biotech Indian biotechnology company and vaccine manufacturer

TN Health Min takes Bharat Biotech's Covaxin shot in Chennai [Video]

TN Health Min takes Bharat Biotech's Covaxin shot in Chennai

The Health and Family Welfare Minister of Tamil Nadu, Dr C Vijayabaskar took Bharat Biotech's Covaxin shot. He took the shot in Chennai on morning of January 22. Dr C Vijayabaskar requested all to get vaccinated and safeguard themselves from COVID-19 pandemic. Billed as the world's largest vaccination programme, covering the entire length and breadth of the country, the drive aims to first inoculate millions of its healthcare and frontline workers and reach an estimated 3 crore people by the end of its first phase. The mega COVID-19 vaccination drive began in India on January 16 (Saturday).

Credit: ANI    Duration: 01:28Published
Healthcare workers should be given choice in vaccines: Karnataka resident doctors [Video]

Healthcare workers should be given choice in vaccines: Karnataka resident doctors

Karnataka Association of Resident Doctors (KARD) has demanded the government to let people choose which COVID-19 vaccine, between Pune-based Serum Institute of India's Covishield and Hyderabad-based Bharat Biotech's Covaxin, they want to take. "Government of India has approved Covishield and Covaxin vaccines. We have all the reports for Covishield. But, Covaxin is still in phase-III trials, where the trial is being done on healthcare workers. We condemn this...Healthcare workers should be given a choice of vaccine," said Dr Dayanand Sagar. GoI rolled out COVID-19 vaccine jab from January 16.

Credit: ANI    Duration: 01:30Published

Related videos from verified sources

Phase 3 trial of Pfizer, Moderna underway, benefits are overwhelming compared to risk: VK Paul [Video]

Phase 3 trial of Pfizer, Moderna underway, benefits are overwhelming compared to risk: VK Paul

NITI Aayog Member (Health) Dr VK Paul said that phase 3 trial of Pfizer, Moderna is still going on but the benefits are overwhelming compared to risk. "World has decided to move forward, take benefit..

Credit: ANI     Duration: 01:14Published
‘Indians are not guinea pigs’: Manish Tewari attacks govt over Covaxin approval [Video]

‘Indians are not guinea pigs’: Manish Tewari attacks govt over Covaxin approval

Congress leader Manish Tewari has lashed out at the government over the approval given to Covaxin for the first phase of trials. The Congress leader raised questions over the efficacy of the..

Credit: HT Digital Content     Duration: 01:40Published
Indians are not guinea pigs: Manish Tewari on rollout of Covaxin [Video]

Indians are not guinea pigs: Manish Tewari on rollout of Covaxin

Congress MP Manish Tewari raised objection on the rollout of Covaxin. Manish Tewari said that government should either not roll out Covaxin till its efficacy and reliability is completely established..

Credit: ANI     Duration: 01:10Published

Related news from verified sources

Phase 1 trial results show Covaxin has tolerable safety, enhanced immunity: Lancet study

India's first indigenous vaccine against COVID-19, Covaxin, showed enhanced immune response without any serious side effects in the participants enrolled for the...
IndiaTimes

All-India vaccine rollout set for next week: Govt

The government will roll out the Covid-19 vaccine next week, with health secretary Rajesh Bhushan saying this was set to happen within 10 days of emergency use...
IndiaTimes